Project: A novel therapeutic antibody and companion diagnostic for non-ischaemic cardiac remodelling

NOVA-CARE aims to establish preclinical efficacy in mouse and porcine disease models for a novel therapeutic monoclonal antibody (mAb) to prevent non-ischaemic heart failure (NI-HF) by targeting EDA-fibronectin (EDA). This protein is upregulated during adverse cardiac remodelling, which leads to heart failure (HF). In addition, a companion diagnostic will be developed using biomarkers linked to EDA expression, to identify patients at risk for developing NI-HF, and to optimize mAb treatment.

Acronym NOVA-CARE (Reference Number: 10421)
Duration 01/10/2016 - 01/10/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24011 EnCare Biotech B.V. Coordinator Netherlands
24012 University Medical Center Utrecht Partner Netherlands
24013 Firalis SAS Partner France
24014 Fusion Antibodies Partner United Kingdom